ElectroCore gammaCore Sapphire CV, Инструкция по эксплуатации, Страница: 27 / 34

64000-00137 Rev 1 27
22. CLINICAL STUDIES
221
A summary of the studies that assessed nVNS in patients with asthma is provided in Table 1:
222
Table 1. Summary of nVNS trials relevant to COVID-19
Study Design N Findings relevant to COVID-19
nVNS for the treatment
of acute asthma
exacerbations Prospective,
multicenter,
open-label
study 4 90 minutes after acute nVNS treatment,
FEV
1
improved from baseline by a mean of
73%, and mean VAS dyspnea score
decreased from 8 (at baseline) to 1
nVNS for the relief of
acute
bronchoconstriction due
to asthma Prospective,
multicenter,
open-label
study 30 90 minutes after acute nVNS treatment, 93%
of patients reported improvement in VAS
dyspnea score, and 86% had improvements
in FEV
1
Abbreviations: COVID-19, coronavirus disease 2019; FEV
1
, forced expiratory volume in 1
second; nVNS, non-invasive vagus nerve stimulation; VAS, visual analog scale.
223
224
225
Note: The remainder of this page was intentionally left blank.
226
227
228